[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603503":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":33,"responsibleParty":52,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":68,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Third Military Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Unilateral primary aldosteronism group",null,"The patients are diagnosed with unilateral primary aldosteronism based on adrenal venous sampling diagnosis, they will treated with spironolactone according to their own condition",[13],"Drug: spironolactone",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","spironolactone","The patients receive spironolactone treatment based on their conditions",[9],[21],"Aldactone",[23],{"name":24,"affiliation":25,"role":26},"Zhiming Zhu, MD","Department of Hypertension and Endocrinology, Daping Hospital, Army Medical University","STUDY_CHAIR",[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Zhencheng Yan, MD","CONTACT","+8613983656682","zhenchengyan@sina.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Daping Hospital, Army Medical Center of PLA","RECRUITING","Chongqing","Chongqing Municipality","400042","China","CN",{"type":43,"coordinates":44},"Point",[45,46],106.55771,29.56026,{"lat":46,"lon":45},[49],{"name":24,"role":30,"phone":50,"phoneExt":10,"email":51},"+8613608313322","hbpcms@sina.com",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Zhiming Zhu","Director of the department of Hypertension & Endocrinology, Daping Hospital","100603503","efficacy-of-spironolactone-combined-with-antihypertensive-drugs-in-patients-with-primary-aldosteronism-100603503",false,"NCT07137364","Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism","Inclusion Criteria:\n\n1. Male or female, aged 30\\~65 years.\n2. PA patients with positive screening tests and saline suppression tests, and with AVS to determine lateralization. These patients have hypertension defined as office blood pressure ≥ 140\u002F90 mmHg, or 24-hour ambulatory blood pressure showing average ≥ 130\u002F80 mmHg, daytime blood pressure ≥ 135\u002F85 mmHg, or nighttime blood pressure ≥ 120\u002F70 mmHg.\n3. Patients with unilateral aldosterone-producing adenoma who decline surgery, or patients with non-adenoma, unilateral PA confirmed by AVS and meeting the above PA-related hypertension criteria.\n4. Provision of written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Hyperkalemia.\n2. Renal impairment or have history of renal disease: serum creatinine \\> 1.5 × upper limit of normal (ULN), dialysis, or nephrotic syndrome.\n3. Other confirmed secondary hypertension: pheochromocytoma, Cushing's syndrome, thyroid disorders, parathyroid disorders, acromegaly, renovascular disease, aortic disorders, chronic alcoholism, or drug dependence, etc.\n4. Adrenal insufficiency.\n5. Heart failure with NYHA class II-IV or stroke.\n6. Acute infection, malignancy, severe arrhythmia, psychiatric disorders, or drug\u002Falcohol abuse.\n7. Significant hepatic dysfunction or have history of liver disease: AST or ALT \\> 2 × ULN, cirrhosis, hepatic encephalopathy, esophageal varices or portosystemic shunt.\n8. Pregnancy or lactation.\n9. Participation in another clinical trial within the past 3 months.\n10. Inability to complete follow-up.\n11. Refusal to provide informed consent.","ALL","30 Years","65 Years",{"count":66,"type":67},350,"ESTIMATED","12 Months","OBSERVATIONAL","The goal of this observational study is to learn about the optimal dose of spironolactone treatment and the long-term outcomes on cardiovascular and cerebrovascular events in patients with lateralized PA who are unwilling to undergo surgery. The main question it aims to answer is:\n\n1. What is the long-term effect of spironolactone treatment for lateralized PA?\n2. What is the optimal dose of spironolactone treatment for the relief of renin inhibition in patients with lateralized PA? Participants will receive spironolactone treatment as part of their regular medical care for more than 12 months, and their clinical indicators, including blood pressure, biochemical remission, cardiovascular and renal damage, and the incidence of cardiovascular and cerebrovascular events, will be analyzed.",[72,73],"Primary Aldosteronism","Hypertension","2025-08-15",{"date":76,"type":77},"2025-08-22","ACTUAL",{"date":79,"type":77},"2022-05-01",{"date":81,"type":67},"2026-04-30",{"name":5,"class":6},1]